Compare DexCom, Inc. (DXCM) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Honest Company Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Honest Company Inc trades at $5.07 (market cap $533.20M). The key difference: DexCom, Inc. is far larger — about 59.8× Honest Company Inc's market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 1,990,155). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Honest Company Inc for 39 Days on average.
| DXCM | HNST | |
|---|---|---|
Market Cap | $31.86B | $533.20M |
Volume | 3,607,070 | 1,990,155 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $5.95 |
52-Week Low | $54.84 | $2.10 |
Typical Hold Time | 62 Days | 39 Days |
Enterprise Value | $31.32B | $436.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
HNST trades at $4.97, up 0.81% with a bearish technical outlook despite recent institutional buying. The company shows mixed fundamentals with Q2 2026 earnings beating estimates but negative profit margins and declining revenue guidance for 2026. Analyst consensus is cautious with a $5.30 price target and 30% buy rating distribution.
The stock faces headwinds from negative profitability and competitive pressures, though strategic exits show early turnaround signs. Upside potential exists if margin improvements continue, but investors should weigh execution risks against institutional accumulation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
